Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
The first global pivotal trial will be in first-line triple-negative breast cancer.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
